Theriva biologics announces first patient dosed in virage, a phase 2b trial of systemically administered vcn-01 in combination with chemotherapy in pancreatic ductal adenocarcinoma

-initiation of phase 2b trial follows clearance from the us food and drug administration (fda) and spanish agency for medicines and health products (aemps)-

TOVX Ratings Summary

TOVX Quant Ranking